Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels

Learn more about:
Related Clinical Trial
Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects. Artificial Intelligence-enable Electrocardiogram for Diagnosis and Outcome in Dyskalemia Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes) A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. Hypomagnesemia Associated With Proton-Pump Inhibitor Use Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia A Study in Children With Hyperkalaemia Between Birth and Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients Potassium Supplementation in CKD Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium Intravenous Fluids in Hospitalised Children Safety of Continuous Potassium Chloride Infusion in Critical Care Comparison of Dexmedetomidine and Remifentanil Infusion During CABG The Impact of Neut During Potassium Chloride Replacement on Pain and Incidence of Phlebitis Efficacy of KCl Plus 0.9%NaCl Compare With KCl Plus 0.45%NaCl Effect of Licorice and Hydrochlorothiazide on Plasma Potassium

Brief Title

Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels

Official Title

Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels: Analysis of Data From the China National Heart Failure Registration Study

Brief Summary

      China National Heart Failure Registration Study (CN-HF) is a nationwide, hospital-based,
      multicentre, prospective registry study sponsored by Ministry of Science and Technology of
      the People's Republic of China. It is aimed to understand the etiology, clinical features and
      treatments of in-hospital HF patients in China [3].

      At present, there are few studies to describe the clinical outcomes of HF patients with
      different sK levels in China. Utilizing the CN-HF database, this study is aimed to describe
      the sK levels of hospitalized HF patients and its impact to the clinical outcomes of
      patients.
    

Detailed Description

      Blood potassium disorders are a common phenomenon in patients with HF, which may be related
      to complications of HF (such as decreased potassium intake, renal insufficiency) and medical
      treatment of HF (such as diuretics, ACEi/ ARB) [9]. It is showed that abnormal changes in sK
      can cause myocardial cell membrane potential instability, increase the risk of malignant
      arrhythmia, and result in a high mortality rate [10].

      Current guidelines in China recommend ACEi/ARBs, β receptor blockers, MRAs, and diuretics for
      treating HF patients . However, β receptor blockers, ACEi/ARB and MRA can also cause
      hyperkalemia , which often leads to dose reduction or even discontinuation of the medicines,
      it affects the patients to benefit from these treatment.

      At present, there are few studies to describe the clinical outcomes of HF patients with
      different sK levels in China. Utilizing the CN-HF database, this study is aimed to describe
      the sK levels of hospitalized HF patients and its impact to the clinical outcomes of
      patients.
    


Study Type

Observational


Primary Outcome

the percentages of patients experiencing a composite of rehospitalization for worsened HF and CV death

Secondary Outcome

 The percentages of patients experiencing rehospitalization for worsened HF

Condition

Hyperkalemia


Study Arms / Comparison Groups

 Hypokalemia group
Description:  defined as sK range (0, 3.5] mmo/L

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

6950

Start Date

December 30, 2021

Completion Date

February 28, 2022

Primary Completion Date

February 28, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  HF patients with sK measurements on admission of hospitalization in CN-HF database
             will be included in this study.

        Exclusion Criteria:

          -  not available for this study
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Jinming Zhou, PhD, +86 18676387265, [email protected]

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT05184998

Organization ID

D9484R00002


Responsible Party

Sponsor

Study Sponsor

AstraZeneca

Collaborators

 Fudan University

Study Sponsor

Jinming Zhou, PhD, Principal Investigator, Fudan University


Verification Date

December 2021